0NN.BE - Avicanna Inc

Berlin - Berlin Delayed Price. Currency in EUR
0.2200
+0.0120 (+5.77%)
As of 09:05PM CEST. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.2080
Open0.2120
Bid0.1730 x N/A
Ask0.2680 x N/A
Day's Range0.2060 - 0.2200
52 Week Range0.1320 - 14.6000
Volume1,850
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 14, 2023 - Aug 18, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 0NN.BE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Shoppers Drug Mart and Avicanna Execute Definitive Asset Purchase Agreement for Avicanna’s Acquisition of the Medical Cannabis by Shoppers Business

      Shoppers Drug Mart and Avicanna Execute Definitive Asset Purchase Agreement for Avicanna’s Acquisition of the Medical Cannabis by Shoppers Business execution of the definitive Asset Purchase Agreement (“Agreement”) between Shoppers Drug Mart® (“Shoppers”) and Avicanna for Avicanna’s acquisition of assets of the Medical Cannabis by Shoppers business (“Business”) with a final closing date set for July 31, 2023 TORONTO, May 29, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TS

    • GlobeNewswire

      Avicanna Announces Results of Annual General and Special Meeting and Provides Corporate Update

      NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN ‎THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A ‎VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, May 17, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development, ‎advancement, and commercialization of evidence-based, cannabinoid-based products‎

    • GlobeNewswire

      Avicanna Reports Q1 2023 Financial Statement

      TORONTO, May 16, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased announce the filing of interim financial statements for the three-month period ending March 31, 2023 (“Q1 2023”). Aras Azadian, CEO stated, “We are pleased to report on our continued progress related to our optimization of op

    • GlobeNewswire

      Avicanna and Northern Green Canada Execute Master Service Agreement to Operationalize MyMedi.ca

      Avicanna and Northern Green Canada Execute Master Service Agreement to Operationalize MyMedi.ca MyMedi.ca to provide Medical Cannabis by Shoppers patients a complete medical cannabis care platform including curated products and services. NGC will facilitate inventory management and fulfillment through its EU GMP-certified and Health Canada licensed infrastructure starting Q2, 2023.Shoppers Drug Mart® (“Shoppers”) has partnered with Avicanna, to transition its Medical Cannabis by Shoppers busines

    • GlobeNewswire

      Avicanna Announces Filing of Annual Financial Statements for Year Ended December 31, 2022

      92% Y-Y increase in Canadian product sales, driven by increased number of commercial SKUs and listings. $4M in revenue, representing 24% Y-Y growth coupled with reduction in SG&A and 35% in EBITA improvements. TORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased announce the

    • GlobeNewswire

      Shoppers Drug Mart partners with Avicanna to transition Medical Cannabis by Shoppers

      Avicanna to introduce MyMedi.ca to medical cannabis patients across Canada Shoppers Drug Mart partners with Avicanna to transition Medical Cannabis by Shoppers Avicanna to introduce MyMedi.ca to medical cannabis patients across Canada. TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is

    • GlobeNewswire

      Avicanna Announces Closing of Non-Brokered Private Placement

      NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, March 21, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, i

    • News Direct

      Avicanna completes first international export of cannabis seeds between Colombia and Spain

      Avicanna CEO Aras Azadian joined Proactive's Natalie Stoberman to discuss the completion of its first export of feminized cannabis seeds to Spain.

    • GlobeNewswire

      Avicanna Expands its Partnership with Viola Brands to the United Kingdom

      Avicanna Expands its Partnership with Viola Brands to the United Kingdom The initial line of Viola-branded products will include proprietary formulations in vaporizer formats for patients with medical authorizations through the Special Access Program.The prescription products will be commercialized in partnership with IPS Pharma, an established company with more than 20 years of experience with unlicensed medicines. The initial line of Viola-branded products will include proprietary formulations

    • News Direct

      Avicanna says 2022 was transformational despite challenging cannabis market

      Avicanna Inc CEO Aras Azadian joined Proactive's Natalie Stoberman with the company's Year in Review including milestones reached in 2022.

    • GlobeNewswire

      Avicanna Announces Warrant and Debenture Repricing and Amendments

      NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, an

    • GlobeNewswire

      Avicanna Subsidiary Santa Marta Golden Hemp S.A.S. Completes First Commercial Export of feminized Cannabis Seeds from Colombia to Spain

      Avicanna's First Commercial Export of Feminized Seeds to Spain Avicanna Subsidiary Santa Marta Golden Hemp completed First Commercial Export of Feminized Seeds from Colombia to Spain This export marks Avicanna’s 19th new international market for Avicanna and the 16th for Aureus branded products. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX

    • GlobeNewswire

      Avicanna Announces Organizational Change in Avicanna LATAM S.A.S

      NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, an

    • GlobeNewswire

      Avicanna Announces Promotion of Phillip Cardella to Chief Financial Officer and Closing of Non-Brokered Private Placement

      NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial-stage, international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based, cannabinoid-based products, t

    • GlobeNewswire

      Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the RHO Phyto™ CBG Transdermal Gel Topical Product

      The real-world evidence study will be conducted in Montreal, Quebec, with Santé Cannabis and will evaluate the efficacy of the product on patients with musculoskeletal pain and inflammation Sante Cannabis Sante Cannabis / Avicanna TORONTO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is

    • GlobeNewswire

      Avicanna Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market

      Influid Water-soluble Nanotechnology Avicanna's Patent-Pending Influid Technology Inside Viola Water-Soluble THC Infuser Developed through Avicanna’s scientific platform, the patent-pending technology provides infusion of a range of cannabinoids into various beverages Initial commercial use of the technology is a THC beverage infuser under the Viola brand available in Ontario through the Ontario Cannabis Store and expanding into other adult use and medical channels during Q4 2022 TORONTO, Nov. 2

    • GlobeNewswire

      Avicanna Reports Q3 2022 Financial Statement

      TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, November 14, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-b

    • GlobeNewswire

      Avicanna Announces Extension of Term Loan

      TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid based products, announces that it has entered into a extension agreement (the “Extension Agreement”) in connection with its senior secured term loan previously announced on August 19, 2021 (the “Term Loan”). In accordance with the Extension Agreement,

    • GlobeNewswire

      Avicanna Files Complete Patent Specifications Relating to a Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

      Recent in-vivo studies conducted in partnership with the University of Toronto confirm Formulation Candidate’s anti-seizure properties allowing for formalization of the patent applicationTORONTO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has formalized i

    • GlobeNewswire

      Avicanna Introduces a New Medical Cannabis Education Online Portal, “Avicenna Academy” for Health Care Professionals

      Avicenna Academy Avicenna Academy The education portal provides modules, case studies and other resources related to medical cannabis for Health Care Professionals Established with the support of experts in the fields of pain management, neurology, and dermatology, the portal is designed to address potential gaps in knowledge and training related to the potential use of cannabis in a medical context TORONTO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN

    • GlobeNewswire

      Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto

      Dr. Mac Burnham’s team will explore Avicanna’s drug candidate and its proprietary combination of cannabinoids in pre-clinical model for seizures. Avicanna further expands its current research and commercial focus in Epilepsy which is supported by current medical cannabis sales and on-going research with UHN TORONTO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focu

    • GlobeNewswire

      Avicanna Announces Results of Annual General and Special Meeting

      TORONTO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated July 28, 2022 (the “Circular”) were elected as directors of the Company at Avicanna’s annual general and special m

    • GlobeNewswire

      Avicanna Announces Closing of Strategic Private Placement

      NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it

    • GlobeNewswire

      Avicanna Reports Q2 2022 Financial Statement

      NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the fili

    • GlobeNewswire

      Avicanna and Ei. Ventures Enter into an Agreement to Develop and Commercialize Adaptogen Nutraceuticals

      Psilly™ Avicanna and Ei. Ventures Psilly™ branded functional fungi-based products will be developed by Avicanna utilizing Avicanna’s proprietary delivery systems and scientific platform TORONTO, July 20, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that the Company has entered